1-3 of 3
Xi Luo
Close
Sort by
Journal Articles

C-terminal binding protein 2 is a novel tumor suppressor targeting the MYC-IRF4 axis in multiple myeloma

Clinical Trials & Observations
Coty Hing Yau Cheung, Chi Keung Cheng, Kam Tong Leung, Chi Zhang, Chi Yan Ho, Xi Luo, Angel Yuet Fong Kam, Tian Xia, Thomas Shek Kong Wan, Herbert Augustus Pitts, Natalie Pui Ha Chan, Joyce Sin Cheung, Raymond Siu Ming Wong, Xiao-Bing Zhang, Margaret Heung Ling Ng
Journal: Blood Advances
Blood Adv (2024) 8 (9): 2217–2234.
https://doi.org/10.1182/bloodadvances.2023010218
Published: 2024
Includes: Supplemental data
Journal Articles

Revision of RUNX1 variant curation rules

Simone Feurstein, Xi Luo, Mancy Shah, Taylor Walker, Nikita Mehta, David Wu, Lucy A. Godley
Journal: Blood Advances
Blood Adv (2022) 6 (16): 4726–4730.
https://doi.org/10.1182/bloodadvances.2022008017
Published: 2022
Includes: Supplemental data
Journal Articles

ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants

Xi Luo, Simone Feurstein, Shruthi Mohan, Christopher C. Porter, Sarah A. Jackson, Sioban Keel, Michael Chicka, Anna L. Brown, Chimene Kesserwan, Anupriya Agarwal, Minjie Luo, Zejuan Li, Justyne E. Ross, Panagiotis Baliakas, Daniel Pineda-Alvarez, Courtney D. DiNardo, Alison A. Bertuch, Nikita Mehta, Tom Vulliamy, Ying Wang, Kim E. Nichols, Luca Malcovati, Michael F. Walsh, Lesley H. Rawlings, Shannon K. McWeeney, Jean Soulier, Anna Raimbault, Mark J. Routbort, Liying Zhang, Gabriella Ryan, Nancy A. Speck, Sharon E. Plon, David Wu, Lucy A. Godley
Journal: Blood Advances
Blood Adv (2019) 3 (20): 2962–2979.
https://doi.org/10.1182/bloodadvances.2019000644
Published: 2019
Includes: Supplemental data